Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients.
Madelaine BeckettJan DutzKun HuangPublished in: RMD open (2024)
Upadacitinib appears to be effective in targeting cutaneous manifestations of refractory inflammatory DM. Further research is still needed to validate its efficacy on a broader population scale.
Keyphrases
- end stage renal disease
- ejection fraction
- oxidative stress
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- type diabetes
- rheumatoid arthritis
- cancer therapy
- interstitial lung disease
- drug delivery
- skeletal muscle
- smoking cessation
- replacement therapy
- systemic sclerosis
- myasthenia gravis